Changes in Th17 cells frequency and function after ozone therapy used to treat multiple sclerosis patients

Background

Multiple sclerosis is an autoimmune condition in which the immune system mistakenly attacks the protective covering of nerve fibres in the brain and spinal cord. A subset of immune cells called Th17 cells - a type of T-helper lymphocyte that produces the inflammatory signalling protein interleukin-17 (IL-17) - has been repeatedly implicated in driving this inflammatory damage. Researchers investigating complementary approaches for multiple sclerosis have looked at whether treatments that influence the wider immune system, including ozone therapy, might also alter the behaviour of these Th17 cells. This study set out to examine whether a course of ozone therapy changed the frequency (how many Th17 cells were present) and the function (how active they were) in people already living with multiple sclerosis.

Study design

The study involved a group of multiple sclerosis patients who underwent a course of ozone therapy, with blood samples analysed to assess the Th17 cell profile before and after treatment. The full text and abstract of this paper are not openly available through standard open-access channels, so the exact patient numbers, ozone administration protocol and laboratory techniques used could not be independently confirmed for this summary. Studies of this type typically assess Th17 cell frequency and cytokine output using blood-based immune cell analysis.

Findings

The published title confirms that changes in both the frequency and the function of Th17 cells were observed following ozone therapy in this patient group. However, because the full results, statistical significance and effect sizes sit behind a journal paywall, this summary cannot state the direction, size or clinical significance of those changes with confidence. Readers wanting the precise findings should consult the original paper via its DOI.

What the authors concluded

The authors' full discussion and conclusions were not accessible for independent verification at the time of writing. Based on the paper's title and its publication in a peer-reviewed multiple sclerosis journal, the study appears to support the broader idea that ozone therapy can influence immune cell populations relevant to multiple sclerosis, consistent with ozone therapy's known general immunomodulatory properties. This should be read as a general observation rather than a restatement of the authors' specific conclusions.

Limitations of this study

This summary has an important limitation: the full abstract and results of this paper were not available through open-access sources at the time of writing, so key details - sample size, statistical analysis, ozone dosing protocol and any comparison groups - could not be independently verified. More broadly, single studies of immune cell markers in small patient groups need replication in larger, controlled trials before firm conclusions can be drawn, and changes measured in blood samples do not automatically translate into confirmed improvements in multiple sclerosis symptoms or disability. Anyone considering ozone therapy alongside multiple sclerosis treatment should discuss it with their neurologist or treating specialist.